NEW YORK, July 21, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inves

Guggenheim analyst Brad Canino maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy and lower

Amova Asset Management Americas Inc. reduced its stake in shares of Ionis Pharmaceuticals, Inc. (NAS

The ATTR-CM and tominersen setbacks drove an excessive selloff without impairing Ionis's wholly owne

NEW YORK, July 16, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors

Wall Street analysts change ratings for Pentair, Intellia Therapeutics, Etsy, Nutrien, and Ionis Pha

SAN FRANCISCO, July 15, 2026 (GLOBE NEWSWIRE) -- Investors in Ionis Pharmaceuticals, Inc. (NASDAQ: I

BIIB's Alzheimer's drug data presentation reaffirms a phase II setback as investors weigh plans to a

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that i

Biogen Inc. (Nasdaq: BIIB) today announced data from the Phase 2 CELIA study evaluating diranersen,

RBC Capital analyst Luca Issi maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Outperform and

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) today announced that the first participant has been dosed

Ionis and AstraZeneca's Phase 3 ATTR-CM trial misses its primary goal, analyst says the outcome

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Ionis Pharmaceuticals (NASDAQ:IONS)

Morgan Stanley analyst Michael Ulz maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Overweigh

Barclays analyst Eliana Merle maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Overweight and

Canaccord Genuity analyst Gary Nachman maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy a

Citigroup analyst Eric Joseph maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy and lowers

Ionis Pharmaceuticals (NASDAQ:IONS) affirms FY2026 sales outlook from $875.000 million-$900.000 mill

Jefferies analyst Akash Tewari maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy and lower

Needham analyst Joseph Stringer maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy and lowe

Gainers Virax Biolabs Group (NASDAQ:VRAX) shares rose 178.9% to $8.87 during Thursday's regular

U.S. stock futures advanced on Thursday, as the Dow Jones, Nasdaq 100, and S&P 500 indices rose,

Ionis and AstraZeneca said Phase 3 eplontersen missed its primary ATTR-CM endpoint, while secondary

Gainers Virax Biolabs Group (NASDAQ:VRAX) stock increased by 134.0% to $7.44 during Thursday's

U.S. stock futures mixed, Dow down 0.1%. Levi Strauss shares down 6.1%, Noah Holdings down 14%, Ioni

Stocks moving: RPGL +54.5%, EDBL +42.5%, SDOT +27.4%, BJDX +24.6%, AP +19.9%, SUNE +18%, ALNY +15.3%

Study missed primary endpoint of composite outcome of cardiovascular (CV) mortality and recurrent CV

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) today announced that it has completed enrollment in the pi

Goldman Sachs analyst Salveen Richter maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Neutra

Ionis wins FDA approval for Tryngolza in severe hypertriglyceridemia and signs a Recordati licensing

Leerink Partners analyst Mani Foroohar maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Outpe

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Ionis Pharmaceuticals (NASDAQ:IONS)

- Recordati brings deep rare disease expertise and proven capabilities in commercialization, access

GSK partnered with Sino Biopharmaceutical to advance hepatitis B drug bepirovirsen in China while la

Companies Reporting Before The Bell • Gatos Silver (NYSE:GATO) is estimated to report quarterly ear

Companies Reporting Before The Bell • Rio Tinto (NYSE:RIO) is projected to report earnings for its

Stocks That Hit 52-Week Lows On Monday

Stocks That Hit 52-Week Lows On Thursday

Stocks That Hit 52-Week Lows On Friday